Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

BACKGROUND: The objective of the study was to evaluate the economics of dacomitinib and gefitinib in the first-line treatments for EGFR-positive advanced or metastatic non-small cell lung cancer (NSCLC) from a US payer perspective. METHODS: We developed the partition survival model to compare the li...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Longfeng, Li, Na, Liu, Maobai, Zheng, Bin, Wu, Zhijuan, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168962/
https://www.ncbi.nlm.nih.gov/pubmed/34093040
http://dx.doi.org/10.2147/CMAR.S293983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168962/
https://www.ncbi.nlm.nih.gov/pubmed/34093040
http://dx.doi.org/10.2147/CMAR.S293983

Ejemplares similares